Bart Neyns
Vrije Universiteit Brussel(BE)Universitair Ziekenhuis Brussel(BE)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Immunotherapy and Immune Responses, Glioma Diagnosis and Treatment, Melanoma and MAPK Pathways
Most-Cited Works
- → Pembrolizumab versus Ipilimumab in Advanced Melanoma(2015)5,779 cited
- → Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial(2015)2,648 cited
- → Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer(2018)2,022 cited
- → Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer(2007)1,996 cited
- → Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)(2017)1,220 cited
- → Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study(2009)1,182 cited